Can a common supplement stop severe COVID? early trial tests MitoQ
NCT ID NCT05381454
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether the dietary supplement MitoQ could prevent severe viral infections, like COVID-19, in adults who had close contact with a sick person. Eighty asymptomatic adults were given MitoQ or no treatment and monitored for illness. The goal was to see if the supplement reduces infection rates and symptom severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mitoquinone/mitoquinol mesylate (MitoQ)
- What this could lead to
- If it works, this could point toward a simple supplement to prevent severe viral illness after exposure.
- What could go wrong
- This is an early, small study (80 people) with no blinding, so results may not be reliable or generalizable. The supplement may not prevent illness or reduce severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIVIRAL TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a virus tip the balance? unraveling lung bacteria in cystic fibrosis
- Can a new drug shield lungs from COVID-19's worst damage?